Puma Biotechnology (PBYI) Peer Comparison

$9.55

$0.14 (1.49%)

As on 04-Sep-2026 16:00EDT

Market cap

$493 Mln

Revenue (TTM)

$231 Mln

P/E Ratio

18.4

P/B Ratio

3.4

Div. Yield

0 %

Edit

	Puma Biotechnology (PBYI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Market cap ($ Mln)	493	16,504	17,747	14,622	12,501
Revenue ($ Mln)	231	2,782	1,054	2,436	1,284
Net Profit ($ Mln)	26.72	491.50	755.85	860.62	-325.10
Net Margin (%)	11.55	17.67	71.69	35.33	-25.32
RoE (%)	19.87	110.09	--	42.98	-57.72
Price to Earnings	18.37	34.72	20.93	18.56	--
Price-To-Book	3.44	38.18	10.51	7.95	23.94

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Puma Biotechnology (PBYI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Operating Revenue	231.24	2,782.29	1,054.37	2,435.92	1,283.94
Cost of Revenue	58.20	1,982.07	103.47	85.67	109.42
Gross Profit	170.21	760.62	588.53	2,236.43	902.26
Operating Expenses	142.61	216.81	841.45	1,378.74	1,497.13
Operating Profit (EBIT)	30.44	583.40	109.45	971.51	-322.62
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	31.17	598.92	101.11	1,035.47	-325.10
Provision for Tax	4.45	107.42	-654.74	174.84	0.00
Profit after Tax (Net Income)	26.72	491.50	755.85	860.62	-325.10
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Puma Biotechnology (PBYI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Shareholder's Funds	138.54	433.86	1,435.90	1,843.76	523.72
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	4.37	187.89	384.48	288.55	346.72
Current Liabilities	49.83	1,435.43	464.70	361.93	374.20
Total Liabilities	216.30	1,975.47	1,302.02	2,844.42	1,259.59

Assets ($ Mln)

	Puma Biotechnology (PBYI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Non-Current Assets	47.66	1,006.90	895.24	1,243.41	45.47
Current Assets	145.07	1,050.29	1,389.84	1,250.82	1,199.18
Total Assets	216.30	1,975.47	1,302.02	2,844.42	1,259.59
Total Debt*	4.82	120.10	449.89	165.93	347.75
Net Current Assets	95.25	-385.14	925.52	888.90	824.98

Cashflow ($ Mln)

	Puma Biotechnology (PBYI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Cash From Operating Activities	41.80	713.22	51.77	884.27	-189.55
Cash Flow from Investing Activities	-36.19	-31.14	-8.15	350.44	32.32
Cash from Financing Activities	-45.20	-860.39	34.89	-969.59	255.98
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Puma Biotechnology (PBYI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
ROCE (%)	19.14	53.56	-30.01	32.82	-31.49
ROE (%)	19.87	110.09	163.18	42.98	-57.72
ROA (%)	10.34	15.64	31.68	29.32	-22.97
EBIT Margin (%)	15.00	21.13	5.73	31.04	-18.97
Net Margin (%)	11.55	17.67	71.69	35.33	-25.32
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Puma Biotechnology (PBYI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Revenue Growth (%)	-2.86	24.67	114.85	9.23	149.04
EBIT Growth (%)	-33.31	18.70	136.39	-3.99	9.16
Net Profit Growth (%)	-44.86	17.50	378.76	42.89	-15.32
EPS Growth (%)	-47.32	26.84	353.27	50.42	-0.64
Book Value Growth (%)	26.13	164.02	816.12	-0.70	-42.66

Valuation Ratios

	Puma Biotechnology (PBYI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Price / Earnings	9.85	36.06	-59.76	15.79	-45.32
Price / Book Value	3.44	38.18	10.51	7.95	23.94
Dividend Yield (%)	0.00	0.00	0.00	0.00	0.00
EV/EBITDA	8.90	27.00	230.43	13.21	-39.74
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Puma Biotechnology (PBYI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Debt to Equity	0.00	0.00	0.27	0.00	0.65
Short term debt to equity ratio	0.00	0.00	0.05	0.00	0.00
Current Ratio	2.91	0.73	2.99	3.46	3.20
Quick Ratio	2.64	0.73	2.32	3.38	2.94
Interest Coverage	9.86	--	1.62	--	-9.32

Operating Efficiency Ratios

	Puma Biotechnology (PBYI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Debtors to sales (%)	14.73	15.88	21.25	13.74	14.98
Asset Turnover	0.90	0.89	0.44	0.83	0.91
Receivable days	68.51	50.42	85.52	43.48	35.88
Inventory Days	44.71	--	1,056.70	96.17	354.23
Payable days	33.18	6.26	331.01	147.97	300.79
Cash Conversion Cycle	80.04	--	811.21	-8.32	89.33

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly